Innostar

Founded in 2010, InnoStar has successfully supported global pharmaceutical and biotech companies with drug discovery, ADME, PK/PD, toxicology, biomarkers, and bioanalysis services. With state-of-the-art facilities across China and the U.S. and a team of over scientists, we have enabled hundreds of IND and NDA/BLA approvals worldwide. InnoStar is GLP-certified by multiple international authorities, including the U.S. FDA, NMPA, and OECD, ensuring compliance with global regulatory standards. Our mission is to accelerate innovative drug development and support our clients in bringing life-saving therapies to patients worldwide. Service experience We have completed over 13,700 projects for more than 770 sponsors. These studies have been submitted in support of over 370 INDs and 18 NDAs/BLAs for innovative drugs in China and 2 NDAs/BLAs in the United States, over 90 INDs in the United States, the European Union, South Korea, and Australia, etc. Data updated to: Dec 31, 2023. InnoStar is committed to providing one-stop service solutions to our sponsors in China and abroad. We are striving to be the scientific and technological innovation pioneer, new drug R&D accelerator, and human life and health guardian. InnoStar was listed on the STAR Market of Shanghai Stock Exchange on September 3, 2024 (Stock code: 688710).